Name | PCSK9-IN-13 |
---|
Description | PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM[1]. |
---|---|
Related Catalog | |
In Vitro | PCSK9-IN-13(compound 3f) (0.1 or 1 μM) 可剂量依赖性的恢复 HepG2 肝细胞对 LDL 的摄取[1]。 |
In Vivo | PCSK9-IN-13(compound 3f) (3.28 or 16.4 mg/kg/day, s.c., 14 days) 在雄性 C57BL/6 小鼠中,剂量为 3.28 mg/kg 时,小鼠没有表现出总胆固醇降低,然而剂量为 16.4 mg/kg 时显示显著降低了总胆固醇血浆水平约 10%,并表现出优异的生物利用度[1]。 |
References |
Molecular Formula | C30H33N5O2 |
---|---|
Molecular Weight | 495.62 |